Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 3 (January 20), 2005: pp. 576-584
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.01.180

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v23,p5276)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le Cesne, A.
Right arrow Articles by Nielsen, O.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Cesne, A.
Right arrow Articles by Nielsen, O.S.

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

A. Le Cesne, J.Y. Blay, I. Judson, A. Van Oosterom, J. Verweij, J. Radford, P. Lorigan, S. Rodenhuis, I. Ray-Coquard, S. Bonvalot, F. Collin, J. Jimeno, E. Di Paola, M. Van Glabbeke, O.S. Nielsen

From the Institut Gustave Roussy, Villejuif; Centre Leon Bérard, Lyon; Centre Leclerc, Dijon, France; Royal Marsden Hospital, London; Christie Hospital, Manchester; Weston Park Hospital, Sheffield, UK; U.Z. Gasthuisberg, Leuven; EORTC Data Center, Brussels, Belgium; Rotterdam Cancer Institute, Rotterdam; Antoni van Leuuwenhoekhuis, Amsterdam, the Netherlands; Pharma-Mar, Tres Cantos, Spain; Aarhus University Hospital, Aarhus, Denmark

Address reprint requests to Axel Le Cesne, MD, Department of Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France; e-mail: lecesne{at}igr.fr

PURPOSE: This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m2 as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced soft tissue sarcoma.

PATIENTS AND METHODS: Patients with documented progressive advanced soft tissue sarcoma received ET-743 as second- or third-line chemotherapy. Antitumor activity was evaluated every 6 weeks until progression, excessive toxicity, or patient refusal.

RESULTS: One hundred four patients from eight European institutions were included in the study (March 1999 to November 2000). A total of 410 cycles were administered in 99 assessable patients. Toxicity mainly involved reversible grade 3 to 4 asymptomatic elevation of transaminases in 40% of patients, and grade 3 to 4 neutropenia was observed in 52% of patients. There were eight partial responses (PR; objective regression rate, 8%), 45 no change (NC; > 6 months in 26% of patients), and 39 progressive disease. A progression arrest rate (PR + NC) of 56% was observed in leiomyosarcoma and 61% in synovialosarcoma. The median duration of the time to progression was 105 days, and the 6-month progression-free survival was 29%. The median duration of survival was 9.2 months.

CONCLUSION: ET-743 seems to be a promising active agent in advanced soft tissue sarcoma, with no cumulative toxicities. The 6-months progression-free survival observed in advanced soft tissue sarcoma compares favorably with those obtained with other active drugs tested in second-line chemotherapy in previous European Organisation for the Research and Treatment of Cancer trials. The median overall survival was unusually long in these heavily pretreated patients mainly due to the high number of patients who benefit from the drug in terms of tumor control.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
Ann OncolHome page
M. von Mehren, R. J. Schilder, J. D. Cheng, E. Temmer, T. M. Cardoso, F. G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R. B. Cohen
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
Ann. Onc., October 1, 2008; 19(10): 1802 - 1809.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
I. Ray-Coquard, A. Le Cesne, J. S. Whelan, P. Schoffski, B. N. Bui, J. Verweij, S. Marreaud, M. van Glabbeke, P. Hogendoorn, and J.-Y. Blay
A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens
Oncologist, April 1, 2008; 13(4): 467 - 473.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. Verweij
Other Endpoints in Screening Studies for Soft Tissue Sarcomas
Oncologist, April 1, 2008; 13(suppl_2): 27 - 31.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
P. G. Casali
Clinical Decision-making in Rare Tumors: What Is Needed from Clinical Trials
ASCO Educational Book, January 1, 2008; 2008(1): 530 - 533.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Tascilar, W. J. Loos, C. Seynaeve, J. Verweij, and S. Sleijfer
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
Oncologist, November 1, 2007; 12(11): 1351 - 1360.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. G. Soares, A. E. Escargueil, V. Poindessous, A. Sarasin, A. de Gramont, D. Bonatto, J. A. P. Henriques, and A. K. Larsen
From the Cover: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
PNAS, August 7, 2007; 104(32): 13062 - 13067.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. G. Maki
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
Oncologist, August 1, 2007; 12(8): 999 - 1006.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. B. Herrero, C. Martin-Castellanos, E. Marco, F. Gago, and S. Moreno
Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin
Cancer Res., August 15, 2006; 66(16): 8155 - 8162.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay
ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas
Oncologist, November 1, 2005; 10(10): 827 - 832.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Sleijfer, C. Seynaeve, and J. Verweij
Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care
Oncologist, November 1, 2005; 10(10): 833 - 841.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Verweij
Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas?
J. Clin. Oncol., August 20, 2005; 23(24): 5420 - 5423.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online